← All candidates
One insider buy in the last year — $100.8K in all.
44 filings on record.
AMLXAmylyx Pharmaceuticals, Inc.
NasdaqGS · Healthcare · $3.64B
$32.63
-1.57% · Sep 16
One insider buy in the last year — $100.8K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy● 30 sells◆ 2 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$3.64B
Float
97.2M
87% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Firestone Karen
Bought $100.8K on Dec 23 — 8,100 sh @ $12.45, held direct, 13% of their stake.
1 of 1 position beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
39 more transactions on Pro →Context
Wall St
$23.40 avg target
-28.3% vs today · 10 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$0.37 act−$0.03
Q4 '25−$0.30 act+$0.04
Q3 '25−$0.37 act+$0.06
Q2 '25−$0.46 act−$0.01
Coverage
Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data?Insider Monkey · 06-30Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take ShapeMarketBeat · 06-10A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Its Recent Share Price ReboundSimply Wall St. · 06-01
The file stays open
44 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice